138 related articles for article (PubMed ID: 11452866)
1. Distinct endobronchial expression of matrix-metalloproteinases (MMP) and their endogenous inhibitors in lung cancer.
Reichenberger F; Eickelberg O; Wyser C; Perruchoud AP; Roth M; Tamm M
Swiss Med Wkly; 2001 May; 131(19-20):273-9. PubMed ID: 11452866
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer.
Suzuki M; Iizasa T; Fujisawa T; Baba M; Yamaguchi Y; Kimura H; Suzuki H
Invasion Metastasis; 1998-1999; 18(3):134-41. PubMed ID: 10474026
[TBL] [Abstract][Full Text] [Related]
4. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
5. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas.
Görögh T; Beier UH; Bäumken J; Meyer JE; Hoffmann M; Gottschlich S; Maune S
Head Neck; 2006 Jan; 28(1):31-9. PubMed ID: 16265652
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases and their inhibitors in malignant and autoreactive pericardial effusion.
Lamparter S; Schoppet M; Christ M; Pankuweit S; Maisch B
Am J Cardiol; 2005 May; 95(9):1065-9. PubMed ID: 15842972
[TBL] [Abstract][Full Text] [Related]
8. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
10. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
13. [Activity of matrix metalloproteinases -2 and -9 (MMP-2 and MMP-9) and content of their tissue inhibitors in endometrial cancer--a preliminary study].
Bogusiewicz M; Stryjecka-Zimmer M; Rechberger T
Ginekol Pol; 2007 May; 78(5):366-72. PubMed ID: 17867327
[TBL] [Abstract][Full Text] [Related]
14. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
Maeta H; Ohgi S; Terada T
Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
[TBL] [Abstract][Full Text] [Related]
15. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease.
Lorenzl S; Albers DS; Narr S; Chirichigno J; Beal MF
Exp Neurol; 2002 Nov; 178(1):13-20. PubMed ID: 12460604
[TBL] [Abstract][Full Text] [Related]
16. Imbalance between Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Promotes Invasion and Metastasis of Head and Neck Squamous Cell Carcinoma.
Stanciu AE; Zamfir-Chiru-Anton A; Stanciu MM; Popescu CR; Gheorghe DC
Clin Lab; 2017 Oct; 63(10):1613-1620. PubMed ID: 29035450
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis.
Sutinen M; Kainulainen T; Hurskainen T; Vesterlund E; Alexander JP; Overall CM; Sorsa T; Salo T
Br J Cancer; 1998 Jun; 77(12):2239-45. PubMed ID: 9649139
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury.
Fligiel SE; Standiford T; Fligiel HM; Tashkin D; Strieter RM; Warner RL; Johnson KJ; Varani J
Hum Pathol; 2006 Apr; 37(4):422-30. PubMed ID: 16564916
[TBL] [Abstract][Full Text] [Related]
19. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
